Business
Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018
Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018.
About this update from Abattis Bioceuticals Corp
[{"type":"text","content":"\nVANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd.\n\n \n \n \n \n \n \n \n \n \n \n \n Abattis and Vergence unveil “Comfort” a new product line targeting Chronic Pain & Inflammation\n \n \n \n \n \n \n \n \n\n “According to a report from the Industry of Medicine, more than 100 million people in North America suffer from chronic pain and inflammation1,” stated Rob Abenante, Abattis President and CEO.  “That same report estimates the pain-price tag for medical treatments and lost productivity at more than $600 billion annually1, making chronic pain and inflammation major drains on the economy. With Comfort, we hope to address a severely disabling condition that affects a large proportion of our population.” The Nielsen Company states market size for over-the-counter pain relief grew from $3.7 billion in 2014 to $4.2 billion in 20172. At the same time, the number of deaths associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”) and opioids, as reported by the United States Centers for Disease Control and Prevention, has also grown. Clearly, there is an urgent need for effective and safe solutions to address the growing problem of chronic pain and inflammation. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e5b472f2-e983-4e60-98bc-cb1ad92b0ebb Dr. Brazos Minshew, MSc, ND and President of the Abattis Medical Advisory Board, explains, “Chronic pain occurs when internal systems within our body break down and fail to produce important endogenous chemicals. One of our body’s key pain management systems works through the production of bioactive lipids known as endocannabinoids which bind to and activate the CB-1 and CB-2 cannabinoid receptors. When activated, CB-1 and CB-2 modulate neural activity, helping our bodies cope with pain without being overwhelmed. Our body’s other principal pain manage...